NCT06904365
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Completed
Not specifiedAges 18–50ObservationalWashington University School of MedicineInvestigator-initiated
~10 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:HyperSight cone beam computed tomography (CBCT) scanETHOS 2.0
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of ovarian visualization
Measured over Estimated to be 5 days
Conditions
Where it's being run
1 sites across 1 statesMissouri1
Study leadership
- Michael Waters, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Biologic female
Age between 18 and 50 years old (inclusive)
Clinically premenopausal (defined as having active, regular menstruation without vasomotor symptoms)
At least one of two ovaries readily visualized on diagnostic CT or MR imaging as confirmed by radiologist
Planning to receive radiation therapy (for any indication)
Ability to understand and willingness to sign an IRB-approved written informed consent document.
Exclusion
Prior pelvic radiation
Prior cancer therapies that are known to impact ovarian function
Prior diagnosis of ovarian insufficiency/failure or menopause
Clinically peri- or post-menopausal
For patients \> 45 years old, if there is a clinical history of vasomotor symptoms OR irregular periods, then the patient must be excluded.
For patients ≤ 45 years old, if there is a history of vasomotor symptoms consistent with menopause OR irregular menstruation for ≥3 months OR recent changes in their menstrual cycle \> 14 days, then the patient must be excluded.
Surgically removed or transposed ovaries
Pregnant and/or breastfeeding
What this trial measures
- Incidence of ovarian visualizationEstimated to be 5 days
Defined as being able to delineate at least one ovary (if only one is visible, must be the same ovary) for ≥60% of CBCT sessions per patient.